Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | ACR | P10323 | 3/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014056 | 0.75 | MAPT (0.48) | PARP10MAPTSMN1; SMN2PARP1CYP2C19 | |
| SCHEMBL890993 | 0.74 | TDP1 (0.53) | MAPTHSD17B10PRSS1TSHRPOLB | |
| Hydrochloric Acid SCHEMBL891074 | 0.74 | MAPT (0.47) | PARP10MAPTSMN1; SMN2PARP1CYP2C19 | |
| SCHEMBL19809404 | 0.73 | SERPINE1 (0.43) | PARP10MAPTKMT2ASMN1; SMN2ESR1 | |
| SCHEMBL6170616 | 0.73 | KMT2A (0.63) | PARP10MAPTKMT2ASMN1; SMN2ESR1 | |
| SCHEMBL31119217 | 0.73 | KMT2A (0.63) | PARP10MAPTKMT2ASMN1; SMN2ESR1 | |
| SCHEMBL16148210 | 0.73 | PARP10 (0.47) | PARP10MAPTKMT2ASMN1; SMN2ESR1 | |
| SCHEMBL19809453 | 0.72 | KMT2A (0.45) | MAPTKMT2ASMN1; SMN2ESR1ESR2 | |
| SCHEMBL28320252 | 0.71 | MAPT (0.51) | PARP10MAPTKMT2ASMN1; SMN2ESR1 | |
| SCHEMBL27639137 | 0.71 | KMT2A (0.51) | PARP10MAPTKMT2ASMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
| US-8071575-B2 | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071575-B2 | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2009-05-07 | — | — | US | disclosed |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2009-05-07 | — | — | US | disclosed |
| WO-2008103951-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | PARP10 2668/4885MAPT 4451/4885KMT2A 3983/4885 |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | PARP10 2668/4885MAPT 4451/4885KMT2A 3983/4885 |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | PARP10 2668/4885MAPT 4451/4885KMT2A 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.